In the past week, ACRS stock has gone down by -12.72%, with a monthly decline of -17.16% and a quarterly plunge of -51.00%. The volatility ratio for the week is 7.04%, and the volatility levels for the last 30 days are 6.72% for Aclaris Therapeutics Inc The simple moving average for the last 20 days is -14.00% for ACRS stock, with a simple moving average of 6.31% for the last 200 days.
Is It Worth Investing in Aclaris Therapeutics Inc (NASDAQ: ACRS) Right Now?
The stock has a 36-month beta value of 0.52. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ACRS is 90.65M, and at present, short sellers hold a 5.54% of that float. On February 28, 2025, the average trading volume of ACRS was 834.28K shares.
ACRS) stock’s latest price update
Aclaris Therapeutics Inc (NASDAQ: ACRS)’s stock price has plunge by 0.26relation to previous closing price of 1.95. Nevertheless, the company has seen a -12.72% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-02-27 that Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
Analysts’ Opinion of ACRS
Many brokerage firms have already submitted their reports for ACRS stocks, with H.C. Wainwright repeating the rating for ACRS by listing it as a “Buy.” The predicted price for ACRS in the upcoming period, according to H.C. Wainwright is $20 based on the research report published on December 23, 2024 of the previous year 2024.
Leerink Partners gave a rating of “Outperform” to ACRS, setting the target price at $7 in the report published on November 19th of the previous year.
ACRS Trading at -21.28% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.19% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -20.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.68% lower at present.
During the last 5 trading sessions, ACRS fell by -14.73%, which changed the moving average for the period of 200-days by +63.25% in comparison to the 20-day moving average, which settled at $2.2710. In addition, Aclaris Therapeutics Inc saw -21.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Mehra Anand, who purchase 666,666 shares at the price of $2.25 back on Nov 19 ’24. After this action, Mehra Anand now owns 710,030 shares of Aclaris Therapeutics Inc, valued at $1,499,998 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 206,025 shares at $1.24 during a trade that took place back on Aug 05 ’24, which means that Leonard Braden Michael is holding 14,250,000 shares at $256,357 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.54 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -1.37. The total capital return value is set at -0.25. Equity return is now at value -84.46, with -62.91 for asset returns.
Currently, EBITDA for the company is -141.93 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.99. The receivables turnover for the company is 78.95for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
To sum up, Aclaris Therapeutics Inc (ACRS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
